Akèy › Kansè Ezofajyen › Michigan › Grand Rapids
Etid klinik pou Kansè Ezofajyen nan Grand Rapids, MI
14 etid pou Kansè Ezofajyen ap chèche patisipan nan sit nan ak bò kote Grand Rapids (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
- START Midwest Cancer and Hematology Centers of W Michigan, Grand Rapids
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
Ap rekriteVolontè an sante akeyi
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
- Trinity Health Grand Rapids Hospital, Grand Rapids
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
Pan-tumor MRD Study
Ap rekriteEtid obsèvasyon
- The Cancer & Hematology Centers (CHC), Grand Rapids
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Ap rekriteFaz 1
- BAMF Health Inc., Grand Rapids
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Ap rekriteFaz 1
- BAMF Health Inc., Grand Rapids
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- START Midwest, Grand Rapids
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Ap rekriteEtid obsèvasyon
- Cancer & Hematology Centers of Western Michigan, Grand Rapids
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Ap rekriteFaz 3
- Research Site, Grand Rapids
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Ap rekriteFaz 1/2
- The Cancer and Hematology Centers ( Site 8912), Grand Rapids
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Ap rekriteFaz 1/2
- The Cancer and Hematology Centers ( Site 6912), Grand Rapids
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Ap rekriteFaz 1
- START Midwest /ID# 248685, Grand Rapids
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Ap rekriteFaz 1/2
- START Midwest, Grand Rapids
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
Ap rekriteFaz 1/2
- BAMF Health, Inc., Grand Rapids
Etid Kansè Ezofajyen nan lòt vil
- Houston, TX36 etid
- Boston, MA23 etid
- New York City, NY22 etid
- Nashville, TN19 etid
- St. Louis, MO17 etid
- Pittsburgh, PA15 etid
- Los Angeles, CA15 etid
- Baldwin Park, CA14 etid
- Philadelphia, PA13 etid
- San Antonio, TX12 etid
- Dallas, TX11 etid
- Arlington, VA11 etid
Lòt etid nan Grand Rapids
- Kansè Poumon ki pa ti selil44 etid
- Kansè kolorektal40 etid
- Kansè (tout kalite)28 etid
- Kansè nan tete26 etid
- Kansè ovè24 etid
- Kansè Metastatik22 etid
- Kansè pwostat19 etid
- Kansè Endomèt18 etid
- Kansè lestomak18 etid
- Kansè pankreyas18 etid
- Melanom17 etid
- Karsinòm selil skuamèz tèt ak kou15 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.